Skip to main content
SpringerLink
Log in

Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR)

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

A long latent period of 20 to 30 years may be involved in the multistep process of carcinogenesis represented by prostatic intraepithelial neoplasia (PIN) in the prostate. It is, therefore, possible that progression to a malignant state could be blocked or reversed during this time. Retinoids not only have the ability to block steps in the process of carcinogenesis but they may also modulate or reverse some malignant characteristics of cancer cells. This study focuses on the ability of N-(4-hydroxyphenyl)-retinamide (4-HPR), a synthetic retinoid, to reverse malignant characteristics towards a normal phenotype, using the human prostate carcinoma cell line DU-145. These malignant characteristics include abnormal cell proliferation, intermediate filament expression, motility, invasion, and cell survival. Results show that 1 μM and 10 μM 4-HPR caused 31% and 96% inhibition of growth, while all-trans retinoic acid (ATRA) produced similar effects at 10 and 100 μM, making 4-HPR ten times more effective than ATRA. While DU-145 cells show strong immunostaining for vimentin, treatment with 1 μM 4-HPR for eight days caused a marked decrease in vimentin staining. This was accompanied by a change from an elongated to an epithelial cell morphology. Densitometric analysis of Western blots for vimentin showed a 53% decrease in vimentin expression in 1 μM 4-HPR treated cells. Concomitant with the decrease in vimentin expression, cell motility and invasive ability also decreased by 32% and 52%, respectively. Growth inhibition was accompanied by DNA fragmentation and apoptosis. Exposure of cells to 1 μM 4-HPR caused a marked upregulation of nuclear retinoid receptors RARα and a detectable expression of RARγ. These results suggest that inhibition of growth and vimentin expression, and induction of apoptosis by 4-HPR in prostate cancer cells may occur via a receptor-mediated mechanism involving transrepression of AP-1 by retinoid receptors. We propose that vimentin may serve as a useful intermediate marker for early detection of prostate cancer in biopsy specimens and that 4-HPR may be effective in blocking several steps in prostate carcinogenesis as well as the progression of PIN to invasive carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics. Cancer J Clin 1998; 48: 6–29.

    Google Scholar 

  2. Bostwick DG, Foster CS. Examination of radical prostatectomy specimens: Therapeutic and prognostic significance, In: Foster CS, Bostwick DG, (eds) Pathology of the Prostate, pp. 172–89. Philadelphia, Saunders, 1998.

    Google Scholar 

  3. Hong WK, Sporn MB. Recent advances in chemoprevention of Cancer. Science 1997; 278: 1073–77.

    Google Scholar 

  4. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379–85.

    Google Scholar 

  5. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990; 16: 39–48.

    Google Scholar 

  6. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997; 18: 1225–31.

    Google Scholar 

  7. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor Genes, and applications. Prostate 1997; 30: 136–42.

    Google Scholar 

  8. Webber MM, Waghray A, Bello D, Rhim JS. Mini Review: Proteases and invasion in human prostate epithelial cell lines: Implications in prostate cancer prevention and intervention. Radiat Oncol Invest 1996; 3: 358–62.

    Google Scholar 

  9. Hong WK, Lippman SM, Hittelman WN, Lotan R. Retinoid chemoprevention of aerodigestive Cancer: From basic research to the clinic. Clin Cancer Res 1995; 1: 677–86.

    Google Scholar 

  10. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 1994; 86: 539–43.

    Google Scholar 

  11. Webber MM, Waghray A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1995; 1: 755–61.

    Google Scholar 

  12. Hendrix MJC, Seftor EA, Seftor REB, Trevor KT. Experimental co- expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997; 150: 483–95.

    Google Scholar 

  13. Sommers CL, Skerker JM, Chrysogelos SA, Bosseler M, Gelmann EP. Regulation of vimentin gene transcription in human breast cancer cell lines. Cell Growth & Differ 1994; 5: 839–46.

    Google Scholar 

  14. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997; 18: 1215–23.

    Google Scholar 

  15. de- Feijter AW, Matesic DF, Ruch RJ, Guan X, Chang CC, Trosko JE. Localization and function of the connexin 43 gap-junction protein in normal and various oncogene-expressing rat liver epithelial cells. Mol Carcinog 1996; 16: 203–12.

    Google Scholar 

  16. Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth & Differ 1995; 6: 863–69.

    Google Scholar 

  17. Wang TTY, Phang JM. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 1996; 107: 65–71.

    Google Scholar 

  18. Igawa M, Tanabe T, Chodak GW, Rukstalis DB. N-(4-hydroxyphenyl)retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 1994; 24: 299–305.

    Google Scholar 

  19. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993; 53: 224–6.

    Google Scholar 

  20. Pollard M, Luckert PH, Sporn M. Prevention of primary prostate cancer in Lobund- Wistar Rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991; 51: 3610–11.

    Google Scholar 

  21. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D Analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res; 1995; 55: 5621–27.

    Google Scholar 

  22. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, et al. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of rasCmyc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 1993; 53: 4461–5.

    Google Scholar 

  23. Grandis JR, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF- _and EGFR in head and neck cancer cell lines. Nature Med 1996; 2: 237–40.

    Google Scholar 

  24. Gotz W, Kasper M, Fischer G, Herken R. Intermediate filament typing of the human embryonic and fetal notochord. Cell Tissue Res 1995; 280: 455–62.

    Google Scholar 

  25. Klundert van de FAJM, Jansen HJ, Bloemendal H. Negative regulation of a special, double AP- 1 consensus element in the vimentin promoter: Interference by the retinoic acid receptor. J Cell Physiol 1995; 164: 85–92.

    Google Scholar 

  26. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31: 325–35.

    Google Scholar 

  27. Heatly M, White J, Patterson A, Maxwell P, Whiteside C, Toner P. Intermediate filament expression of ductal carcinoma cells in fine needle aspirates of the breast. Acta Cytol 1997; 41: 717–20.

    Google Scholar 

  28. Takahashi N, Breitman TR. Unassembled (soluble) vimentin in human myeloid leukemia cell line HL60. Eur J Haematol 1994; 53: 78–84.

    Google Scholar 

  29. Takeda M, Nishimura T, Hariguchi S, Tatebayashi Y, Tanaka T, Tanimukai S, Tada K. Study of cytoskeletal proteins in fibroblasts cultured from familial Alzheimer's disease. Acta Neurol Scand 1991; 84: 416–20.

    Google Scholar 

  30. Fraga CH, True LD, Kirk D. Enhanced expression of the mesenchymal marker, vimentin, in hyperplastic versus normal human prostatic epithelium. J Urol 1998; 159: 270–74.

    Google Scholar 

  31. Wernert N, Seitz G. Immunohistochemical Investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol Res Pract 1987; 182: 617–26.

    Google Scholar 

  32. Mostofi FK, Sesterhenn IA, Davis CJ Jr. Prostatic Intraepithelial neoplasia (PIN): Morphological clinical significance. Prostate 1992; 4 (suppl): 71–7.

    Google Scholar 

  33. Battifora H. Assessment of antigen damage in immunohistochemistry: The vimentin internal control. Am J Clin Pathol 1991; 96: 669–71.

    Google Scholar 

  34. Nagle RB, Brawer MK, Kittelson J, Clark V. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 1991; 138: 119–28.

    Google Scholar 

  35. Bussemakers MJG, Verhaegh GWCT, van Bokhoven A, Debruyne FMJ, Schalken JA. Differential expression of vimentin in rat prostatic tumors. Biochem Biophys Res Commun 1992; 182: 1254–59.

    Google Scholar 

  36. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089–94.

    Google Scholar 

  37. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 1994; 59: 126–32.

    Google Scholar 

  38. Lotan R. Retinoids and Apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87: 1655–57.

    Google Scholar 

  39. Oridate N, Lotan D, Mitchell MF, Hong WK, Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemoprevention. J Cell Biochem (suppl) 1995: 23: 80–6.

    Google Scholar 

  40. Hsieh TC, Wu JM. Effects of fenretinide (4- HPR) on prostate LNCaP cell growth, apoptosis, and prostate- specific gene expression. Prostate 1997; 33: 97–104.

    Google Scholar 

  41. Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, et al. Fenretinide: Induction of apoptosis and endogenous transforming growth factor ?in PC-3 prostate cancer cells. Cell Growth & Differ 1997; 8: 101–11.

    Google Scholar 

  42. Widschwendter M, Daxenbichler G, Culig Z, Michel S, Zaimet AG, et al. Activity of retinoic acid receptor-? electively binding retinoids alone and in combination with interferon-? in breast cancer cell lines. Int J Cancer 1997; 71: 497–504.

    Google Scholar 

  43. Meister B, Fink FM, Hittmair A, Marth C, Widschwendter M. Antiproliferative activity and apoptosis induced by retinoic acid receptor-?selectively binding retinoids in neuroblastoma. Anticancer Res 1998; 18: 1777–86.

    Google Scholar 

  44. Toma S, Isnardi L, Riccardi L, Bollag W. Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 1998; 18: 935–42.

    Google Scholar 

  45. Fanjul AN, Domenico D, Pierotti MA, Rideout D, Qiu J, Pfahl M. 4-Hydroxyphenyl-retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996; 271: 22441–46.

    Google Scholar 

  46. McCormick DL, Rao KVN, Dooley L, Steele VE, Lubet RA, et al. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction on Wistar-Unilever Rats. Cancer Res 1998; 58: 3282–88.

    Google Scholar 

  47. Tradati N, Chiesa F, Rossi N, Grigolato R, Formelli F, et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994; 76: 109–11.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Zoology and Medicine, Michigan State University, East Lansing, MI , 48824-1312, USA

    Mukta M. Webber, Diana Bello-DeOcampo, Salmaan Quader, W. Scott Metcalfe & Rebekah M. Sharp

  2. Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI , 48824-1312, USA

    Nestor D. Deocampo

Authors
  1. Mukta M. Webber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Bello-DeOcampo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salmaan Quader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nestor D. Deocampo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Scott Metcalfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rebekah M. Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Webber, M.M., Bello-DeOcampo, D., Quader, S. et al. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis 17, 255–263 (1999). https://doi.org/10.1023/A:1006665616932

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006665616932

Search

Navigation